New “managed access” process for Cancer Drugs Fund to go ahead, NHS England confirmsBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1208 (Published 29 February 2016) Cite this as: BMJ 2016;352:i1208
- Susan Mayor
NHS England has confirmed that from 1 July its Cancer Drugs Fund will operate on a “managed access” basis, meaning that it will fund anticancer drugs for up to two years while the National Institute for Health and Care Excellence (NICE) assesses them.
Introduced in 2010, the fund pays for cancer treatments not recommended by NICE for routine use in the NHS. Such drugs include new treatments that NICE has yet to assess; drugs for rare cancers that are not being appraised by NICE; and drugs rejected by NICE because they were not deemed cost effective.
A recent report by the House of Commons Public Accounts Committee said that the fund needed “significant and urgent …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial